QBIO News and Press, Q BioMed Inc From 11/16/20

Q BioMed's Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer PR Newswire NEW YORK, Nov. 16, 2020 NEW YORK , Nov. 16, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), announces that it has received a patent from the U.S. Paten...

Phoenix, Arizona--(Newsfile Corp. - October 14, 2020) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, Denis Corin, joined Stock Day host Everett Jolly. Jolly began the interview by asking a...

AUSTIN, Texas, Sept. 22, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses init...

NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announces initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone. Q BioMed announced the US-based laun...

NEW YORK , Aug. 26, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical grade therapeutic intended to treat complica...

Named Patient Programs will allow Providers to treat patients with bone metastases pain palliation radiopharmaceutical treatment as of September, 2020 Named Patient Programs will remain in place until the treatment has been commercialised in EU and ROW, which is expected to be complete...

July 22, 2020 Palm Beach, FL – July 22, 2020  – The rising incidence of liver cancer and growing research activities for developing novel treatments plus the availability of newer drugs and treatments coupled with rising awareness among consumer/patients regardi...

Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNe...

AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses the devel...

Q BioMed ( OTCQB:QBIO +1.3% )  announced today that it entered an exclusive Named Patient Program distribution agreement with Caligor Coghlan Pharma Services for its non-opioid metastatic cancer bone pain drug, Strontium, 89. More news on: Q BioMed Inc., Healthcare stocks news R...